Seizure Freedom in Patients with Dravet Syndrome with Contraceptives: A Case Report with Two Patients

Abstract

Dravet syndrome is a rare and malignant epileptic syndrome that is typically resistant to antiepileptic drugs. There is a growing interest in the antiepileptic properties of neurosteroids. Especially progesterone is known to act as an anticonvulsive agent. However, contraceptives that act as orally given neurosteroids often lead to increased seizures in women with epilepsy.

We report on two girls with Dravet syndrome, who gained seizure freedom under therapy with contraceptives. The first patient received an oral contraceptive, a combination of an estrogen, and a gestagen, due to hypermenorrhea. The second received a pure gestagen implant for contraception.

The antiepileptic effect of progesterone is mainly attributed to its conversion into allopregnanolone and related neurosteroids, which are positive modulators of gamma-aminobutyric acid A receptors. It is unclear whether the observed effect of these contraceptives containing synthetic progesterone derivatives may be specific for the Dravet syndrome, and it is unclear whether and how this observation can be used therapeutically.

Keywords

Dravet syndrome - epilepsy - treatment - neurosteroids - contraceptives

^* Dr. Jan Lotte and Dr. Stefan Grothe contributed equally to the manuscript.

• References

• 1 Ceulemans B, Boel M, Leyssens K. , et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012; 53 (07) 1131-1139
• 2 Harkin LA, McMahon JM, Iona X. , et al; Infantile Epileptic Encephalopathy Referral Consortium. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 2007; 130 (Pt 3): 843-852
• 3 Shi XY, Tomonoh Y, Wang WZ. , et al; Epilepsy Genetic Study Group, Japan. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain Dev 2016; 38 (01) 40-46
• 4 Taubøll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015; 28: 3-11
• 5 Reddy DS, Gangisetty O, Wu X. PR-independent neurosteroid regulation of α2-GABA-A receptors in the hippocampus subfields. Brain Res 2017; 1659: 142-147
• 6 Thomas SV. Controversies in contraception for women with epilepsy. Ann Indian Acad Neurol 2015; 18 (03) 278-283
• 7 Velíšková J, Desantis KA. Sex and hormonal influences on seizures and epilepsy. Horm Behav 2013; 63 (02) 267-277
• 8 Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009; 6 (02) 392-401
• 9 Broomall E, Natale JE, Grimason M. , et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 2014; 76 (06) 911-915
• 10 Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epilepsia 2017; 58 (04) 558-564
• 11 Caperelli LM. Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder. Available at: http://files.shareholder.com/downloads/AMDA-31TCR1/4463703640×0×924714/4925E9CA-2694-4CC0-8F0A-6DECE0FCC7F8/MRNS_News_2017_1_23_General_Releases.pdf . Accessed February 12, 2018
• 12 Chiron C. Stiripentol. Neurotherapeutics 2007; 4 (01) 123-125